注射用丹参多酚酸对多发性硬化急性期疗效及血清基质金属蛋白酶9水平的影响

Effect of Salvianolic Acids for Injection on acute multiple sclerosis and serum matrix metalloproteinase-9 level

目的通过观察注射用丹参多酚酸对复发缓解型多发性硬化(RRMS)的疗效,检测血清基质金属蛋白酶9(MMP-9)用药前后含量变化,分析MMP-9与扩展功能障碍状态量表(EDSS)评分、日常生活能力量表(ADL)评分的相关性,评估注射用丹参多酚酸对RRMS急性期患者疗效。方法随机将40例RRMS患者分为两组,各20例。对照组采用糖皮质激素与神经营养药物,观察组在此基础上加用注射用丹参多酚酸,每日1次。两组均治疗14 d。观察两组治疗前、用药14 d后血清MMP-9水平及治疗前、治疗14、28 d后EDSS及ADL评分。结果两组患者治疗14 d后血清MMP-9水平均增高,观察组患者MMP-9水平增高幅度明显低于对照组,差异有统计学意义(P<0.05)。两组患者治疗14 d后及治疗后28 d EDSS评分均明显下降,同组治疗前后比较差异有统计学意义(P<0.05);且观察组EDSS评分降低的程度大于对照组,差异有统计学意义(P<0.05)。两组患者治疗14 d后及治疗后28 d ADL评分均较治疗前升高,同组治疗前后比较差异有统计学意义(P<0.05);且观察组ADL评分高于对照组,差异有统计学意义(P<0.05)。结论注射用丹参多酚酸可以降低RRMS患者MMP-9水平,改善临床症状,提高生存质量,用药后安全有效,无严重不良反应。

Objective Clinical observe the curative effect on multiple sclerosis by Salvianolic Acids for Injection, by detecting the content of MMP-9 in the serum before and after taking the medicine, analyzing the correlation between MMP-9 and EDSS/ADL grade, assess the curative effect on patients with acute phase of RRMS that injected with Salvianolic Acids for Injection. Method(1)Case collect: randomly divide the 40 MS into observation group and control group, 20 cases in each group.(2)Test index: test serum MMP-9 before the first treatment, and after 14 days of initial treatment, review serum MMP-9, testing company test serum MMP-9.(3) Assess EDSS grade and ADL grade before treatment, 14 days after treatment and 28 days after treatment.(4) Dosage regimen:the control group using glucocorticoid and neurotrophic drugs, the observation group on above basis, give Salvianolic Acids for Injection as treatment, once a day. Both groups were treated for 14 days. Results The levels of serum MMP-9 in both groups increased 14 days after treatment. The increase of serum MMP-9 in the observation group was significantly lower than that in the control group(P < 0.05). The EDSS scores of the two groups decreased significantly after 14 days of treatment and 28 days of treatment, and there was a significant difference between the two groups before and after treatment(P < 0.05), and the EDSS scores of the observation group were significantly lower than those of the control group(P < 0.05). The ADL scores of the two groups after14 days of treatment and 28 days of treatment were higher than those before treatment, and the difference between the two groups before and after treatment was statistically significant(P < 0.05);and the ADL scores of the observation group were higher than those of the control group, the difference was statistically significant(P < 0.05). Conclusion Salvianolic Acids for Injection can reduce the MMP-9 levels in multiple sclerosis patients, improve clinical symptoms, improve life quality of patients, the medication is safe and effective, no serious adverse reactions.